A large pharmacoepidemiologic cohort study of over 17,000 US patients admitted directly to ICUs for acute exacerbations of COPD revealed that two-thirds received high-dose systemic corticosteroids (>240 mg/day methylprednisolone equivalent).

Higher doses were linked to worsened clinical outcomes, including longer ICU and hospital stays, extended mechanical ventilation, higher hospital costs, increased need for insulin therapy due to hyperglycemia, and more fungal infections, even after adjustments.

While the study did not identify the ideal dose or duration, it echoes findings from non-ICU COPD exacerbations that “more steroids are not better.” Adopting lower-dose strategies could substantially cut steroid-related adverse events and healthcare costs.

The authors emphasize the need for randomized trials to determine optimal corticosteroid regimens in critically ill COPD patients.

Read More